Friday, 19 Jul 2019

You are here

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

The analysis was narrowed to 18 RCTs and 6981 patients.

The ability of the biologic to yield significant resolution of dactylitis at week 24 revealed the following risk ratios (RRs) versus placebo: 

  • TNFi: RR 2.57 (95% CI: 1.36-4.84)
  • Novel biologics RR 1.88 (95% CI: 1.33-2.65), respectively

Resolution of enthesitis at week 24 revealed:

  • TNFi: RR 1.93 (95% CI: 1.33-2.79)
  • Novel biologics: RR 1.95 (95% CI: 1.60-2.38)

Both the TNFi and novel biologic had overlapping ranges of ACR20 responses:

  • TNFi: RR=2.23, 95% CI: 1.60-3.11
  • Anti-IL-12/23 and IL-17 agents: RR=2.30, 95% CI 1.94-2.72)

Pooled analysis demonstrates agents targeting TNFi, IL-17, and IL-12/23 have equivalent efficacy in managing dactylitis and enthesitis in PsA patients.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Fatigue is Driven by Inflammation, Pain, and Chronicity in Psoriatic Arthritis

Correlates with fatigue were assessed in psoriatic arthritis (PsA) patients in the DANBIO registry and found to be associated with  clinical inflammatory factors, disease duration, and chronic pain.

A toital of 2062 PsA patients in the Danish nationwide registry DANBIO were studied by cross-sectional survey from December 2013 to June 2014.

CAM Use is Common in Psoriasis

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.

The survey was sent to 100,927 NPF members and 219 completed it.

Recommendations for Exercise in Ankylosing Spondylitis

Australian researchers have assessed the problem of exercise in ankylosing spondylitis (AS). After posing 10 questions to 11 experts they have provided evidence and consensus-based ecommendations on exercise in AS.

Biologic Retention in Ankylosing Spondylitis Patients

A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.

A nationwide Swedish Rheumatology register followed 2590 Bio-naïve AS who started a TNFi between 2006–2015.

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.